

DEVELOPMENT SCIENCES: Innovation & Technology

TITLE


Utilizing Model-Based Approach to Simulate Virtual Data in Dose Regimens

SUMMARY

Tecentriq is approved for 1200 mg q3w administration as monotherapy in NSCLC and mUC indications. Identification of alternative dosing regimens that can be used interchangeably would offer patients greater convenience in their treatment. The goal of this work is to utilize a model-based approach to simulate virtual data in dose regimens not tested previously for FDA approval without conducting clinical trials.

IMPACT

- Provide greater patient convenience with an alternative dosing regimen
- Cost effective way to expand label language using a model-based approach



CONTACT

Ben Wu, Senior Scientist, Clinical Pharmacology
wu.benjamin@gene.com



Development
Sciences